LFM-A13 is a highly selective inhibitor of the non-receptor tyrosine kinase BTK (Brutons tyrosine kinase) (IC50 = 2.5 µM). It irreversibly severs the downstream signaling network of the B-cell receptor (BCR) by targeted binding to the BTK kinase catalytic domain, exhibiting excellent anti-leukemic and immunomodulatory effects in models of acute/chronic lymphocytic leukemia and severe autoimmune diseases.
Molecular Weight:
360
Purity:
99.50%
CAS Number:
[62004-35-7]
Formula:
C11H8Br2N2O2
Target:
BTK
T212732
* VAT and and shipping costs not included. Errors and price changes excepted
